Senti Biosciences, Inc.
SNTIHealthcare|Biotechnology|US
$0.16
-0.00 (-2.74%)
Cash / Share
$0.21
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06325748 SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | AML/MDS, CD33 Expressing Hematological Malignancies | P1 | Active | 21 | Open-label | SENTI-202 |
| NCT06652243 Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma | Hepatocellular Carcinoma (HCC) | Early P1 | Recruiting | 12 | Open-label | SN301A |
| NCT04693091 Feasibility of Remote Evaluation and Monitoring of Acoustic Pathophysiological Signals With External Sensor Technology | Respiratory Disease | N/A | Unknown | 10 | Open-label | — |
| NCT05745155 REMAP-WEST-FLARE - FLAg for Review Efficacy Investigation | COPD | N/A | Completed | 200 | Open-label | — |
| NCT04695821 Feasibility of Remote Evaluation and Monitoring of Acoustic Pathophysiological Signals With External Sensor Technology in Covid-19 | Covid19 | N/A | Unknown | 10 | Open-label | — |